Sarah Romano - 01 Mar 2022 Form 4 Insider Report for First Wave BioPharma, Inc. (ENTO)

Role
Chief Financial Officer
Signature
/s/ Sarah Romano
Issuer symbol
ENTO
Transactions as of
01 Mar 2022
Net transactions value
$0
Form type
4
Filing time
02 Mar 2022, 17:02:48 UTC
Previous filing
11 Feb 2022
Next filing
05 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FWBI Stock option (right to buy) Award $0 +150,000 $0.000000 150,000 01 Mar 2022 Common stock, par value $0.0001 per share 150,000 $1.18 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests in three equal annual installments commencing on March 1, 2023.